Overview

This trial is active, not recruiting.

Condition constipation
Treatments nutrabiotix, psyllium
Phase phase 1/phase 2
Sponsor Rush University Medical Center
Start date July 2010
End date October 2017
Trial size 120 participants
Trial identifier NCT01210625, Nutrabiotix

Summary

The investigators hypothesize that daily oral intake of starch-entrapped alginate microspheres (called Nutrabiotix fiber) is well tolerated, exhibits no or minimal "typical" side effects of fiber (e.g. bloating, loose stool, flatulence), can be used as an ideal vehicle to deliver anti-oxidants/anti-inflammatory natural and synthetic substances/agents; and promote gut health by improving bowel habit, by changing the gut microbiota and increasing production of short chain fatty acids, especially butyrate, in the colon and decreasing production of protein putrification (prebiotic effects).

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification bio-equivalence study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator, outcomes assessor)
Arm
(Active Comparator)
Subjects will take 4 capsules containing 1 gram psyllium fiber 3 times a day (12g total per day)
psyllium
12g total per day (4 capsules containing 1 gram psyllium fiber 3 times a day)
(Experimental)
Subjects take a total of 9g of Nutrabiotix a day (3 capsules of 1g Nutrabiotix 3 times a day)
nutrabiotix
Fiber supplement: 9mg or 12mg
(Experimental)
Subjects take a total of 12g of Nutrabiotix a day (4 capsules of 1g Nutrabiotix 3 times a day)
nutrabiotix
Fiber supplement: 9mg or 12mg

Primary Outcomes

Measure
Subject satisfaction
time frame: 2011

Secondary Outcomes

Measure
stool weight
time frame: 2011

Eligibility Criteria

Male or female participants from 18 years up to 65 years old.

Inclusion Criteria: - Healthy, asymptomatic 18 to 65 years subjects with BMI 20-30 and self described unsatisfactory bowel habit Exclusion Criteria: 1. Abnormalities in CBC (Hgb <12 g/dL, platelet count <100 000, WBC <4000 or >10 000); 2. Abnormal liver function tests (ALT, AST, alkaline phosphatase, or bilirubin >1.5 times normal range); 3. Abnormal renal function tests (BUN or creatinine >1.5 times normal range); 4. Low serum albumin (<3 g/dL); 5) Abnormal TSH level; (6) High CRP; (7) Significant GI symptoms (except for constipation or occasional rectal bleeding due to hemorrhoids); (8) Prior intestinal resection; (9) Patient history of GI diseases [except for hemorrhoids or occasional (<3 times a week) heartburn]; (10) Antibiotic use within last 12 weeks prior to enrollment; (11) Lean (BMI <25) or obese (BMI>30) subjects because obesity could be associated with abnormal microbiota; (12) Significant cardiac or respiratory diseases (defined by requiring daily medication for management of their diseases); (13) Severe hypertension (defined as uncontrolled hypertension in spite of therapy, or requirement of more than one medication to treat hypertension; well-controlled, mild hypertension may be included); (14) Insulin-requiring and/or poorly controlled diabetes (well-controlled diabetics with HbA1c <6 may be enrolled); (15) Significant psychological disorders; (16) Drug and/or alcohol abuse; (17) Unwillingness to consent to the study; (18) Plan to have a major change of the dietary habit during the following 5 months; (19) Subjects younger than 18 or older than 65. Older subjects are excluded in this initial study because of high co-morbidity in older subjects. Children are excluded for this initial Phase I study where the safety is not established; (20) Pregnant and lactating women due to lack of information about safety of the product in pregnant and lactating women.

Additional Information

Official title A Randomized, Double Blind, Controlled, Dose Ranging Trial to Compare Nutrabiotix Fiber to Psyllium Fiber in Patients Experiencing Constipation.
Principal investigator Michael Brown, M.D.
Description The long-term objective of our research program is to show that targeted colonic delivery of natural specific fermentable carbohydrates will maintain and promote gut health by changing the gut microbiota [prebiotic effect], by increasing "protective and growth promoting" factors such as butyrate, and enhancing intestinal barrier function. These health-promoting functions may prevent and treat a wide range of disorders associated with an abnormal microbiota (dysbiosis) and/or disrupted gut barrier function. Examples of disorders associated with dysbiosis and disrupted gut barrier (leaky gut) are allergic disorders, inflammatory bowel disease, diverticular disease, colon polyps and cancer, alcoholic liver disease, non-alcoholic steatohepatitis (NASH- the most common liver disease in the USA), and irritable bowel syndrome (IBS, the most common GI illness in the US with a high loss of productivity and a high rate of utilization of health care resources). Nutrabiotix fiber is a prebiotic and is able to promote gut health through changes in the stool microbiota composition favoring saccharolytic bacteria like Bifidobacteria and diminishing proteolytic bacteria like Clostridia. This change in the intestinal microbiota composition should result in increases in the products of carbohydrate fermentation [SCFA] and decreases in the products of protein breakdown [indoles and phenols] in the stool. Also, the fiber is well tolerated and without side effects and is an effective fiber that increases stool bulk and regulates bowel movement.
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by Rush University Medical Center.